Maze, Dawn http://orcid.org/0000-0002-4598-9380
Arcasoy, Murat O.
Henrie, Ryan
Cerquozzi, Sonia
Kamble, Rammurti
Al-Hadidi, Samer
Yacoub, Abdulraheem
Singh, Anurag K. http://orcid.org/0000-0003-1114-9508
Elsawy, Mahmoud http://orcid.org/0000-0001-9872-2471
Sirhan, Shireen
Smith, Elliot
Marcoux, Curtis
Viswabandya, Auro http://orcid.org/0000-0001-9690-4669
Daly, Andrew
Sibai, Hassan
McNamara, Caroline
Shi, Yuliang
Xu, Wei
Lajkosz, Katherine
Foltz, Lynda
Gupta, Vikas http://orcid.org/0000-0002-1419-8607
Article History
Received: 24 August 2023
Revised: 19 October 2023
Accepted: 30 October 2023
First Online: 8 November 2023
Change Date: 26 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-023-02194-y
Competing interests
: DM declares consultancy for Pfizer, advisory board participation for and honoraria from Novartis, honoraria from BMS-Celgene and research support from Takeda. MA has received research support from Gilead, Incyte, CTI BioPharma and Samus Therapeutics. VG has received honorarium, clinical trial funding through institution, and served on advisory boards of Novartis, BMS-Celgene, Abbvie, Pfizer and Sierra Oncology. The other authors have no relevant conflicts to declare.